Cargando…

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report

Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Biyong, Wang, Wei, Tan, Jing, Yuan, Bo, Chen, Guilan, Mo, Xiaofei, Fan, Jieqiong, Yang, Bo, Huang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273654/
https://www.ncbi.nlm.nih.gov/pubmed/34262854
http://dx.doi.org/10.3389/fonc.2021.596732
_version_ 1783721413289443328
author Ren, Biyong
Wang, Wei
Tan, Jing
Yuan, Bo
Chen, Guilan
Mo, Xiaofei
Fan, Jieqiong
Yang, Bo
Huang, Xiaoping
author_facet Ren, Biyong
Wang, Wei
Tan, Jing
Yuan, Bo
Chen, Guilan
Mo, Xiaofei
Fan, Jieqiong
Yang, Bo
Huang, Xiaoping
author_sort Ren, Biyong
collection PubMed
description Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy.
format Online
Article
Text
id pubmed-8273654
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82736542021-07-13 Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report Ren, Biyong Wang, Wei Tan, Jing Yuan, Bo Chen, Guilan Mo, Xiaofei Fan, Jieqiong Yang, Bo Huang, Xiaoping Front Oncol Oncology Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273654/ /pubmed/34262854 http://dx.doi.org/10.3389/fonc.2021.596732 Text en Copyright © 2021 Ren, Wang, Tan, Yuan, Chen, Mo, Fan, Yang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ren, Biyong
Wang, Wei
Tan, Jing
Yuan, Bo
Chen, Guilan
Mo, Xiaofei
Fan, Jieqiong
Yang, Bo
Huang, Xiaoping
Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title_full Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title_fullStr Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title_full_unstemmed Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title_short Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
title_sort efficacy of anlotinib for the treatment of angiosarcoma of the face and neck: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273654/
https://www.ncbi.nlm.nih.gov/pubmed/34262854
http://dx.doi.org/10.3389/fonc.2021.596732
work_keys_str_mv AT renbiyong efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT wangwei efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT tanjing efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT yuanbo efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT chenguilan efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT moxiaofei efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT fanjieqiong efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT yangbo efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport
AT huangxiaoping efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport